Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
IPO Year: 2015
Exchange: NASDAQ
Website: aclaristx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/22/2024 | Buy → Neutral | H.C. Wainwright | |
11/13/2023 | Outperform → Mkt Perform | William Blair | |
10/3/2023 | $22.00 | Outperform | Evercore ISI |
12/14/2022 | $29.00 | Buy | Stifel |
12/1/2022 | $25.00 | Buy | Goldman |
10/6/2022 | $32.00 | Buy | BTIG Research |
7/23/2021 | $27.00 → $32.00 | Buy | Jefferies |
H.C. Wainwright downgraded Aclaris Therapeutics from Buy to Neutral
William Blair downgraded Aclaris Therapeutics from Outperform to Mkt Perform
Evercore ISI initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $22.00
Stifel initiated coverage of Aclaris Therapeutics with a rating of Buy and set a new price target of $29.00
Goldman initiated coverage of Aclaris Therapeutics with a rating of Buy and set a new price target of $25.00
BTIG Research initiated coverage of Aclaris Therapeutics with a rating of Buy and set a new price target of $32.00
Jefferies resumed coverage of Aclaris Therapeutics with a rating of Buy and set a new price target of $32.00 from $27.00 previously
HC Wainwright & Co. reiterated coverage of Aclaris Therapeutics with a rating of Buy and set a new price target of $50.00 from $40.00 previously
Piper Sandler initiated coverage of Aclaris Therapeutics with a rating of Overweight and set a new price target of $30.00
H.C. Wainwright initiated coverage of Aclaris Therapeutics with a rating of Buy and set a new price target of $40.00
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris' Phase 2a clinical trial of ATI-2138, an investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase (JAK) 3, for the treatment of moderate to severe atopic dermatitis (AD). "We are thrilled to have dosed the first patient in this clinical trial, marking an important milestone for our ITK inhibitor programs," said Dr. Neal Walker, Interim President & CEO and Chair of the Bo
WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York. A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website. About Aclaris Therapeutics, Inc. Aclaris Therapeutics,
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update. "With study activities underway for our ATI-2138 Phase 2a trial in moderate to severe atopic dermatitis and the strengthening of our balance sheet through the completion of our royalty purchase agreement wi
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris' future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales of OLUMIANT® (baricitinib) for the treatment of alopecia areata to OMERS, one of Canada's largest defined benefit pension plans. Under the terms of the agreement, Aclaris has received an upfront p
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida. A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website. About Aclaris Therapeutics, Inc. Acl
- Progressing ATI-2138 into Atopic Dermatitis -- Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update. "We are pleased to announce that following a review of the potential development pathways for ATI-2138, our investigational ITK/JAK3 compound with best-in-class potential, we have decided to progress ATI-2138 into a proof-of-concept Phase 2a trial in patients with moderate to
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets. Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The conference call will be webcast live over the internet and can be accessed by logging into the "Investors" page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. The webcast will be archived for at leas
CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update. "As we enter 2024, we are financially strong, focused and motivated," stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. "Returning to the CEO role, I look forward to building on our strong foundation and deep expertise in kinase discovery and development as we look to shape the future of Aclaris." Research and Development Hi
- Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive Officer - WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced leadership changes and that it is undertaking a strategic review of its business. Aclaris and Douglas Manion, M.D. have mutually agreed that Dr. Manion will step down as Aclaris' Chief Executive Officer and President and member of the Board of Directors, effecti
10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
S-8 - Aclaris Therapeutics, Inc. (0001557746) (Filer)
ARS - Aclaris Therapeutics, Inc. (0001557746) (Filer)
DEFA14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)
DEF 14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update. "With study activities underway for our ATI-2138 Phase 2a trial in moderate to severe atopic dermatitis and the strengthening of our balance sheet through the completion of our royalty purchase agreement wi
- Progressing ATI-2138 into Atopic Dermatitis -- Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update. "We are pleased to announce that following a review of the potential development pathways for ATI-2138, our investigational ITK/JAK3 compound with best-in-class potential, we have decided to progress ATI-2138 into a proof-of-concept Phase 2a trial in patients with moderate to
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets. Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The conference call will be webcast live over the internet and can be accessed by logging into the "Investors" page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. The webcast will be archived for at leas
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update. "As we enter 2024, we are financially strong, focused and motivated," stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. "Returning to the CEO role, I look forward to building on our strong foundation and deep expertise in kinase discovery and development as we look to shape the future of Aclaris." Research and Development Hi
— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET — WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA; ATI-450-RA-202). ATI-450-RA-202 is a Phase 2b, randomized, multicenter, double-blind,
- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated Around Year-End 2023 - WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2023 and provided a corporate update. "Throughout the first three quarters of this year, I believe our company has performed remarkably well in terms of executing across our clini
- Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023 - WAYNE, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2023 and provided a corporate update. "During the second quarter of this year, we continued to make positive strides across our clinical development pipeline, most notably through the completion of enrollment in our Phase 2b trial of zunsemetinib in patients with rheumatoid arthritis, wh
- Management to Host Conference Call at 8:00 AM ET Today – WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2023 and provided a corporate update. "The first quarter of 2023 represented another period of continued progress advancing our clinical stage development programs toward important data milestones," stated Doug Manion, M.D., Chief Executive Officer of Aclaris. "As we continue to move toward data catalysts for zunsemetinib in rheumatoid arthritis and psoriatic arth
WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets. Management will conduct a conference call at 8:00 AM ET on the same day to discuss Aclaris' financial results and to provide a corporate update, including a summary of final results from the Phase 2a trial of zunsemetinib (ATI-450) in subjects with moderate to severe hidradenitis suppurativa. The conference call will be webcast live over
WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2022 and provided a corporate update. "The past year for Aclaris was marked by tremendous execution across our organization notably highlighted by our clinical development programs and our proprietary kinase-focused drug discovery platform," stated Doug Manion, M.D., Chief Executive Officer of Aclaris. "We enter 2023 well positioned to capitalize on that momentum with multiple data read-outs expected, begin
CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023, co-founder
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations. "We are very excited that we continue further strengthening our team through the addition of experienced industry veterans with successful track records," said Neal Walker, Chief Executive Officer of Aclaris. "Bob brings to Aclaris considerable experience leading investor relations programs across a number of various therapeutic sectors." Mr. Doody has nearly 20 years of biotechnology i
Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as President and Chief Operating Officer. Dr. Manion will be responsible for overseeing day-to-day operations, continuing to develop Aclaris' infrastructure and helping Aclaris develop its vision and overall strategic direction alongside Neal Walker, Aclaris' CEO, and Aclaris' board of directors. "We are excited to strengthen our leadership team by welcomi
Appoints Gail Cawkwell, MD, PhD, as Chief Medical Officer WAYNE, Pa., June 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of Gail Cawkwell, MD, PhD, as Chief Medical Officer, effective today. "We are excited to welcome Dr. Cawkwell to Aclaris at this time as we are executing on a number of clinical programs," said Dr. Neal Walker, President and CEO of Aclaris. "Her leadership experience in pharmaceutical development as well as her clinical background will be extremely valuable in navigating the strategic directi
Appoints James Loerop as Chief Business Officer WAYNE, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of James Loerop as Chief Business Officer, effective January 31, 2022. "We are excited to welcome Jim to Aclaris," said Dr. Neal Walker, President and CEO of Aclaris. "His experience as a business development leader in the life sciences industry will be extremely valuable in executing our global business development strategy for our drug development pipeline." Mr. Loerop brings over two decades of exper
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
The Dow Jones index closed higher by more than 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. BranchOut Food The Trade: BranchOut Food Inc. (NASDAQ:BOF) Director Byron Riche Jones bought a total of 41,755 shares at an average price of $0.99. To acquire these shares, it cost around $41,337. What's Happening: On June 26, Branchout Foo
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Neutral.
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 Million Milestone -
The Dow Jones index closed higher by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Aclaris Therapeutics The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 352,397 shares at an average price of $1.15. To acquire these shares, it cost around $405,894. What's Happening: On May 7, Ac
The Dow Jones index closed lower by around 0.2% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Aclaris Therapeutics The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 1,611,200 shares at an average price of $1.11. To acquire these shares, it cost around $1.78 million. What's Happening: On M
Gainers Sharps Technology (NASDAQ:STSS) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 9.75% to $2.25. The market value of their outstanding shares is at $3.2 million. Lucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 6.89% to $0.93. The market value of their outstanding shares is at $1.6 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 6.4% to $1.33. The company's market cap stands at $5.6 million. Aclaris Therapeutics (NASDAQ:ACRS) shares rose 5.4% to $1.17. The market value of their outstanding shares is at $83.3 mi
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 42.86 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $1.37 million by 75.04 percent. This is a 5.14 percent decrease over sales of $2.53 million the same period last year.
The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Aclaris Therapeutics The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Director Andrew Kenneth William Powell acquired a total of 14,500 shares an average price of $1.24. To acquire these shares, it cost around $17,955. What’s Happening: Aclari
Aclaris Therapeutics (NASDAQ:ACRS) reported its Q4 earnings results on Tuesday, February 27, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Aclaris Therapeutics beat estimated earnings by 12.0%, reporting an EPS of $-0.3 versus an estimate of $-0.34. Revenue was up $9.82 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.07 which was followed by a 1.0% drop in the share price the next day. Here's a look at Aclaris Therapeutics's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.48 -0.45 -0.44 -0.45 EPS Actual -0.41 -0.42 -0.42 -0.41 Revenue Estimate 1.57M 1.90M